ABVC

ABVC Biopharma, Inc.

0.72 USD
+0.01 (+0.98%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ABVC Biopharma, Inc. stock is down -30.1% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 8 June’s closed higher than May.

About ABVC Biopharma, Inc.

ABVC BioPharma, Inc. develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer. ABV-1504 has completed Phase II clinical trials for major depressive disorders. ABV1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.